- Home
- DTIL vs NRXP Comparison
DTIL vs NRXP Comparison
Compare DTIL & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- NRXP
- Stock Information
- Founded
- DTIL 2006
- NRXP 2015
- Country
- DTIL United States
- NRXP United States
- Employees
- DTIL N/A
- NRXP N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- DTIL Health Care
- NRXP Health Care
- Exchange
- DTIL Nasdaq
- NRXP Nasdaq
- Market Cap
- DTIL 55.3M
- NRXP 58.5M
- IPO Year
- DTIL 2019
- NRXP N/A
- Fundamental
- Price
- DTIL $5.39
- NRXP $3.07
- Analyst Decision
- DTIL Strong Buy
- NRXP Strong Buy
- Analyst Count
- DTIL 2
- NRXP 5
- Target Price
- DTIL $47.00
- NRXP $31.40
- AVG Volume (30 Days)
- DTIL 84.4K
- NRXP 415.5K
- Earning Date
- DTIL 11-03-2025
- NRXP 11-13-2025
- Dividend Yield
- DTIL N/A
- NRXP N/A
- EPS Growth
- DTIL N/A
- NRXP N/A
- EPS
- DTIL N/A
- NRXP N/A
- Revenue
- DTIL $1,261,000.00
- NRXP N/A
- Revenue This Year
- DTIL N/A
- NRXP N/A
- Revenue Next Year
- DTIL $135.19
- NRXP $395.09
- P/E Ratio
- DTIL N/A
- NRXP N/A
- Revenue Growth
- DTIL N/A
- NRXP N/A
- 52 Week Low
- DTIL $3.61
- NRXP $1.10
- 52 Week High
- DTIL $9.20
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- DTIL 56.34
- NRXP 48.75
- Support Level
- DTIL $5.26
- NRXP $3.19
- Resistance Level
- DTIL $5.94
- NRXP $3.84
- Average True Range (ATR)
- DTIL 0.22
- NRXP 0.25
- MACD
- DTIL 0.02
- NRXP -0.03
- Stochastic Oscillator
- DTIL 55.35
- NRXP 25.00
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.